122 results about "Restenosis" patented technology

The invention discloses a covered stent and a balloon dilatation covered stent system, and relates to the technical field of medical instruments.The covered stent comprises a stent body connected through a tubular covering film, and the covered stent has a non-load state with the zero compression diameter and a load state which has the compression rate relative to the non-load state and is used for supporting blood vessels to recover blood flow; when the compression ratio of the covered stent is 10%, the numerical range of the radial supporting force of the covered stent is 2.0 N / mm-6. 0N / mm. The balloon dilatation covered stent system comprises an elastic pipe sleeve, a balloon, a mandrel and a covered stent, the covered stent, the elastic pipe sleeve, the balloon and the mandrel are sequentially arranged from outside to inside in a sleeving mode, and the two ends of the balloon are sealed with the mandrel; the near end of the elastic tube sleeve is fixedly connected with the mandrel or the near end of the balloon; and the far end of the elastic tube sleeve movably sleeves the balloon. The covered stent can provide moderate support for blood vessels, and the problems of lumen restenosis and stent collapse after an existing covered stent is implanted can be effectively solved.

The invention provides a medical stent and a preparation method thereof.The preparation method comprises the steps that an anti-coagulation coating is arranged on at least part of the surface of the medical stent through physical coating, then an anti-hyperplasia coating is arranged on at least part of the surface of the medical stent through physical coating, the anti-coagulation coating comprises a copolymer, and the anti-hyperplasia coating comprises an anti-hyperplasia coating. A copolymer in the anticoagulant coating contains a zwitterionic unit and an adsorption unit, and the anti-hyperplasia coating contains an anti-hyperplasia drug and a degradable polymer; or, an anti-hyperplasia and anti-coagulation integrated coating is arranged on at least part of the surface of the medical stent through physical coating, the integrated coating contains a copolymer and an anti-hyperplasia drug, and the copolymer in the integrated coating contains a zwitter-ion unit, an adsorption unit and a degradable unit; the adsorption unit is an ester unit containing a carbon-carbon double bond, and the degradable unit is a 2-methylene-1, 3-dioxane unit. The problem that thrombus and restenosis exist at the same time after the stent is implanted can be solved, the binding force between the coating and the substrate is improved, and the falling risk of the coating is reduced.

The invention relates to the technical field of biomedical materials, in particular to a double-network structure artificial blood vessel with anticoagulation, endothelium promotion and anti-infection functions and a preparation method of the double-network structure artificial blood vessel. The artificial blood vessel comprises a polymer fiber network artificial blood vessel substrate, a microscopic network hydrogel layer penetrating through the polymer fiber network artificial blood vessel substrate, and magnesium-copper alloy particles doped in the hydrogel layer. According to the artificial blood vessel with the double-network structure, the problem that a traditional small-caliber artificial blood vessel is insufficient in mechanical performance is greatly solved, copper ions and magnesium ions are released to the surrounding environment by means of degradation of the magnesium-copper alloy particles in the using process, the microenvironment of the surrounding tissue is adjusted to be alkalescent, nitric oxide is catalytically released, and the mechanical performance of the artificial blood vessel is improved. The artificial blood vessel with the double-network structure is endowed with anticoagulation, endothelium promotion and anti-infection functions. The problems of restenosis and insufficient endothelialization of a small-caliber artificial blood vessel in the prior art are comprehensively solved, and the long-term patency rate of the artificial blood vessel is increased.

The invention provides a 4D printing esophageal stent and a preparation method thereof. The esophageal stent comprises a stent main body and a drug-loaded fiber membrane with a core-shell structure, the stent main body is a tubular stent composed of a bionic water lily hollow structure; the diameters of the head end and the tail end of the support body are larger than the diameter of the middle section, and barb structures are arranged on the outer surfaces of the head end and the tail end. The stent main body is a biodegradable shape memory polymer; the drug-loaded fibrous membrane is positioned on the outer surface of the middle section of the stent main body, and the drug-loaded fibrous membrane contains drugs. The 4D printing esophageal stent provided by the invention has excellent compressive bearing capacity and anti-slip capacity, and the drug-loaded fibrous membrane can avoid esophageal restenosis through long-term uniform slow release of drugs, so that the life safety of a patient can be further guaranteed.

A prosthetic heart valve for the treatment of structural heart disease wherein the prosthetic heart valve includes an expandable frame that a) has an open cell geometry in the frame of the prosthetic heart valve that can be used to reduce delivery system size, b) has high radial strength, c) has improved restoration of the physiologic EOA, d) has lower recoil, e) has little or no longitudinal foreshortening, f) allows for proper placement of the bioprosthetic valve in relation to the native commissures of the valve, h) has symmetrical and cylindrical expansion of the prosthetic valve resulting in lower rates of leaflet thrombosis and structural valve deterioration, and / or i) prevents allergic response and restenosis associated with nickel content.

The invention discloses a peripheral vascular punctiform stent system comprising a punctiform stent unit and a delivery assembly unit. The dotted stent unit comprises a plurality of mutually independent dotted stents; the point-shaped supports are sequentially arranged in the length direction of the conveying assembly units. A radial supporting force range associated with the compression ratio is preset for each point-shaped stent unit; when the value of the compression ratio is 10%-55%, the value domain of the radial supporting force of the dotted stent units is 0.15-0.5 N / mm, and the value of the radial supporting force of any dotted stent does not exceed the endpoint value of the value domain of the radial supporting force of the dotted stent units. The radial supporting force range is designed in advance, so that the dotted stent units have redundancy, the stability defect of the dotted stent units after being unfolded in the blood vessel is overcome, unexpected displacement and restenosis of one or more dotted stent units are inhibited, and the original position is maintained for a long time.

The invention provides a sustained-release drug stent for tracheal lesion tissues and a preparation method thereof, and belongs to the technical field of medical instruments. The stent takes a nickel-titanium alloy wire as a base material, after acid pickling, weaving and heat treatment shaping, a drug coating is loaded through multiple steps: firstly, an anti-tumor or anti-inflammatory drug is mixed with a PLGA solution to form nano-particles; then, carrying out chitosan modification and dopamine coating, so as to obtain PLGA-PDA drug carrier nanoparticles; then, nano-particles are sprayed on the surface of the stent to form a drug coating; and finally, coating a PLGA-HA composite solution to enhance the performance of the stent. By optimizing the material and the coating structure, accurate slow release of the medicine is achieved, relapse and restenosis of tracheal lesion tissue are effectively inhibited, the treatment effect and safety are improved, and a new scheme is provided for tracheal lesion treatment.

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

The invention belongs to the technical field of molecular biology diagnosis and treatment, and relates to application of a reagent for detecting or inhibiting FN1 and a product for diagnosing or preventing and treating vascular restenosis. The expression level of the FN1 in a vascular restenosis sample is remarkably increased, and the FN1 can promote phenotypic transformation of vascular smooth muscle cells (VSMC). Meanwhile, further research proves that the FN1 has better diagnosis efficiency on the diagnosis of the vascular restenosis, and is higher in sensitivity, specificity and accuracy, so that the FN1 can be used for effectively diagnosing the vascular restenosis. In addition, in-vivo experiments prove that VSMC phenotypic transformation can be inhibited and vascular restenosis can be improved by inhibiting FN1 expression. The invention provides a new direction for research and development of vascular restenosis related diagnosis and prevention and treatment products, and has a good clinical application prospect.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention belongs to the technical field of medical instruments, and particularly relates to an intracranial drug balloon catheter and a preparation method thereof. A two-time spraying method is adopted, the humidity of carrier gas during two-time spraying is controlled, an amorphous-state drug coating and a crystalline-state combined drug coating are formed on the surface of the balloon catheter, and the drug can be released, permeated and stored within 90 s after the balloon catheter adheres to the wall; further, the technical effects of effectively and lastingly inhibiting the intimal hyperplasia and reducing the restenosis rate are achieved, and the method has excellent trafficability and traceability and can adapt to the complex environment condition of intracranial tortuous blood vessels; meanwhile, the drug coating firmness and release performance can be achieved at the same time, and neurotoxic complications caused by drug falling during in vitro, delivery and expansion are avoided.

The invention relates to a flexible conductive intravenous stent based on functional electrical stimulation. The invention belongs to the fields of biomedical engineering and the like. The PCL-Gr extravascular stent is prepared by utilizing an electrostatic spinning technology, and the PCL-Gr extravascular stent wraps the periphery of the transplanted vein to provide necessary mechanical support for the transplanted vein so as to maintain the structural stability of the transplanted vein, so that the risk of restenosis caused by hemodynamic change is reduced. And meanwhile, functional electrical stimulation is accurately applied to transplanted veins by utilizing conductivity, so that double mechanisms of promoting endothelialization and inhibiting smooth muscle cell proliferation are achieved, and the risk of intimal hyperplasia is effectively reduced.

Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such as pulmonary hypertension, restenosis, essential hypertension, atherosclerosis, stroke, sepsis, or a viral infection, such as a coronavirus infection, SARS-CoV-2. The methods comprise administering to the patient an amount of a compound as described herein effective to treat the patient. NCOA7-activating compounds and compositions also are provided. Also provided is a gene editing method of reducing inflammation or an inflammatory condition in a patient having a C at SNP rs 11154337, comprising editing the C to a G.

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

The present technology provides methods of reducing vein graft injury comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and / or NADH to the vein to be grafted prior to surgical implantation of the vein graft in a subject. Additionally, the present technology provides methods of improving vein graft health and preventing or treating post-operative restenosis and also provides bioavailable nanoparticles comprising NAD+ and / or NADH and a coating comprising a human cell membrane for use in such methods.

The invention relates to the technical field of vascular interventional therapy instruments, and discloses an excimer laser ablation system and method for restenosis after Budd-Chiari syndrome interventional therapy, the excimer laser ablation system comprises a controller, a pulse transmitting module and a reference element arranged in a catheter, and the system performs periodic self-calibration based on the reference element; according to the method, associated photoacoustic signals are collected and processed to identify tissue types, selective ablation of lesion tissues and boundary self-stop when healthy tissues are touched are further achieved, traditional open-loop energy delivery is converted into a closed-loop self-control process with real-time information interaction capacity, and the method has the advantages of being simple in structure, convenient to operate and high in practicability. The ablation operation tail end can sense the tissue boundary in situ and achieve automatic stopping, so that the problem that healthy tissue is damaged due to uncontrollable energy application is solved, the safety of an operation is improved, and the advantages of being high in precision, few in complication, capable of achieving repeated treatment and the like are achieved.

The invention discloses a pharmaceutical composition for preventing esophageal stenosis. The pharmaceutical composition consists of glucocorticoid and sesame oil, the glucocorticoid is triamcinolone acetonide or dexamethasone. The pharmaceutical composition provided by the invention is prepared from 1-5 parts by weight of triamcinolone acetonide and 10-15 parts by weight of sesame oil; or 5-10 parts by weight of dexamethasone and 100 parts by weight of sesame oil. The medicine composition is simple, raw materials are low in price, and mass production and use are facilitated. Practical research finds that the pharmaceutical composition provided by the invention can be used for preventing esophageal stenosis caused by disease reasons, such as esophageal stenosis after large-area endoscopic submucosal dissection (the dissection area is 2 / 3 or above) of esophageal premature cancer, esophageal restenosis after benign esophageal stenosis dilation treatment and the like.

The invention provides an intravascular stent and a manufacturing method thereof. The intravascular stent comprises a stent near end, a stent body and a stent far end which are sequentially arranged in the axial direction of the intravascular stent, and the supporting force of at least one of the stent near end and the stent far end is smaller than that of the stent body. By means of the configuration, the stimulation effect of one end or two ends of the stent on non-lesion blood vessels can be reduced, endothelialization of the non-lesion blood vessels is better facilitated, and the risk of long-term restenosis is reduced.

The invention relates to a method and device for predicting the risk of restenosis after intravascular treatment of a TARAS patient, a storage medium and a program product. The method comprises the following steps: acquiring target preoperative clinical data and target iconography characteristics collected for a detection object; calculating a risk score based on the target preoperative clinical data and the target iconography features; the risk score is compared with a first threshold value, an auxiliary prediction result of the detection object is determined according to a comparison result, and the auxiliary prediction result is used for representing the restenosis risk of the detection object. The invention aims to provide a model for evaluating the post-PTA restenosis risk of a severe TARAS patient by using anatomical risk factors and other clinical risk factors, so that the risk of an intravascular treatment technology can be quantified, and the clinical popularization and application of the intravascular treatment technology can be promoted.

The invention discloses a cardiovascular stent coating capable of rapidly reconstructing endothelium and releasing nitric oxide for a long time, a preparation method and a stent. The cardiovascular stent coating comprises a dopamine / hexamethylenediamine-copper coating and multiple functional substances combined with the dopamine / hexamethylenediamine-copper coating, and the multiple functional substances comprise an NO precursor, endothelial polysaccharide with the anticoagulation characteristic and growth factors capable of specifically adhering EC. The cardiovascular stent coating provided by the invention is grafted with various functional substances such as endothelial polysaccharide, growth factors capable of specifically adhering EC, NO precursors and the like, so that the defects of low NO yield, poor anticoagulation effect, incapability of quickly promoting re-endothelialization in an early stage and the like of a traditional coating are favorably improved. According to the invention, the cardiovascular stent is endowed with various functions of adhering EC, increasing anticoagulation, providing enough NO under the condition of existence or absence of an endogenous NO donor and the like, so that rapid reendothelialization is promoted, thrombosis and restenosis are prevented, and the long-term curative effect and safety of the cardiovascular stent are finally improved.

The invention relates to the technical field of vascular therapy, in particular to a nano-drug and a preparation method thereof.The nano-drug comprises a nano-carrier, a therapeutic drug and cross-linked protein are loaded on the nano-carrier, the cross-linked protein is at least partially loaded on the surface of the nano-carrier, and the cross-linked protein is at least one of silk fibroin, sericin and silk fibroin peptide; the therapeutic drug is at least partially loaded in the nano-carrier. On one hand, cross-linked protein on the surface of the nano-carrier is promoted to be cross-linked with protein in a blood vessel by initiating the photosensitive cross-linking agent, and the nano-carrier is anchored in the blood vessel, so that the risk that nano-drug particles are eluted from the blood vessel wall is greatly reduced; on the other hand, cross-linking of cross-linked protein on the surface of the nano-carrier can be promoted by initiating the photosensitive cross-linking agent, so that the surface of the nano-carrier is gelatinized, the slow release speed of the nano-drug anchored in the blood vessel is more lasting, and further effective drug concentration can be maintained for a long time, restenosis of the blood vessel is inhibited, and the treatment effect is improved.

The invention discloses a zinc alloy stent as well as a preparation method and application thereof. The zinc alloy bracket comprises a zinc-based alloy matrix and a coating arranged on the zinc-based alloy matrix, the coating comprises a zinc layer and a poly-racemic lactic acid coating containing an active drug. According to the zinc alloy stent, the pure zinc layer and the poly-racemic lactic acid coating containing the active medicine are arranged on the zinc-based alloy matrix, so that the early-stage degradation speed of an early-stage zinc alloy implant is slowed down, the number of degradation products is controlled, stimulation of the degradation products to blood vessels is reduced, the probability of occurrence of thrombosis and restenosis in the early-stage and middle-stage is reduced, and the stent has a good application prospect. And the early mechanical property and biocompatibility of the instrument are ensured.

The present application provides a kind of vascular stenosis treatment device, it includes treatment component, the treatment component includes: balloon, the wall of the balloon has a plurality of first holes for liquid to pass, the balloon has unexpanded state and expanded state;Cover, the cover is covered outside the balloon and expands along with the balloon expansion, the cover has a plurality of second holes, when the balloon is in the expanded state, the aperture of the first hole is less than the aperture of the second hole.The vascular stenosis treatment device of the present application can realize accurate positioning, and the cover has a limiting effect on the liquid, so that the drug can be more uniformly and effectively act on the required position of the blood vessel wall, thereby improving the utilization rate of the drug, reducing the incidence of vascular restenosis, and improving the treatment effect.

The present application relates to an airway stent comprising a stent body and a covering membrane disposed on the stent body. The covering membrane comprises a covering section and folded-back sections, the covering section covering the stent body, and the folded-back sections being formed by folding back from ends of the covering section. The airway stent provided by the present application forms folded-back sections at both ends of the airway stent by using the covering membrane to increase thickness at both ends of the airway stent, while also enhancing soft support at both ends of the airway stent, thereby providing radial support to end portions at both ends of the airway stent without introducing rigid stimuli. This configuration reduces rigid friction of the ends of the stent body against a tracheal wall, thereby reducing stimuli to tracheal wall tissue and lowering the likelihood of airway restenosis.

The utility model provides a cutting woven covered stent, which relates to the technical field of medical instruments, and comprises a cutting skeleton, a woven mesh and an ePTFE membrane, the cutting skeleton is designed by combining an open loop and a closed loop, and the two ends of the stent have a good anchoring effect in vivo; and the middle part is of an open-loop structure, and through the support of the woven mesh, the whole body has good support performance and also has flexibility. The stent composed of the cutting framework, the woven mesh and the ePTFE membrane is arranged, the cutting framework is designed by combining an open loop and a closed loop, and the two ends of the stent have a good anchoring effect in the body; and the middle part is of an open-loop structure, and through the support of the woven mesh, the whole body not only has good support performance, but also has flexibility. The outer layer is coated with the ePTFE membrane, so that the coverage area on plaques is larger, the probability that the plaques fall off from stent meshes can be effectively reduced, and micro-embolism after the plaques fall off is prevented. The ePTFE membranes on the inner layer and the outer layer are dip-coated with the drug-loaded coatings, proliferation of vascular smooth muscles is inhibited, and intravascular restenosis is prevented.

The invention discloses an endovascular interventional targeted drug delivery system for treating pulmonary artery stenosis, and belongs to the technical field of minimally invasive interventional therapy. Compared with the prior art, the intravascular targeted drug delivery system balloon dilatation catheter provided by the invention can be used for interventional therapy of chronic thrombotic pulmonary hypertension (CTEPH). The endovascular intervention targeted drug delivery system for treating pulmonary artery stenosis, provided by the invention, adapts to a pulmonary artery anatomical path, and ensures the pushing property and flexibility in a complex delivery process. Anti-proliferation (such as paclitaxel and derivatives thereof or rapamycin and derivatives thereof) and anticoagulant drugs (such as heparin and tirofiban hydrochloride) are loaded on the surface of the balloon, mechanical expansion and local targeted drug delivery are achieved, and restenosis and thrombosis are inhibited.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

Disclosed herein is a biomimetic torpedo that can circumvent existing hurdles for RNA therapies. That is, RNA therapeutics can be harbored inside a torpedo shell made of neutrophil membranes in hybrid with a liposome membrane, which enables lesion targeting and shielding from immunogenicity. Further disclosed herein is a biomimetic targeting system that involves a neutrophil cell membrane capsule that encapsulates a therapeutic RNA.

The invention discloses a targeted drug release type cardiovascular stent system for preventing vascular restenosis, and belongs to the technical field of interventional medical instruments. Comprising a stent skeleton matched with a coronary artery lumen, a micro-fluidic drug storage bin assembly integrally embedded in the stent skeleton, an intelligent driving assembly correspondingly assembled in a micro-fluidic channel and a targeted release mechanism arranged in the stent skeleton, the micro-fluidic drug storage bin assembly comprises a plurality of independently sealed drug storage bins and corresponding micro-fluidic channels, and the intelligent driving assembly achieves sequential unlocking according to the vascular repair stage through a Venturi tube, a body temperature response type diameter adjusting piece, a sequential degradation sealing piece and an elastic self-reset blocking sealing piece, dynamically adjusts the drug release amount along with the body temperature gradient, and achieves the purpose of repairing the blood vessel. And the liquid medicine is directionally released to a diseased region through the array microtube. The full-period staged precise drug delivery can be realized, the unbalance and unexpected release of the drug are avoided, and the effect and clinical reliability of the stent for preventing the vascular restenosis are improved.

This invention discloses a 3D-printed helical biodegradable anti-inflammatory vascular stent and its preparation method, belonging to the field of vascular stents. The invention uses multiple helical support wires arranged into a tubular shape, with the ends connected in a serpentine transitional manner. The helical support wires are connected by connecting ribs, and the surface is coated. This invention is biodegradable after use, avoiding the harm caused by permanent retention in the body, and has a lower restenosis rate compared to metal stents. The surface of the vascular stent is coated with a spermidine-containing coating to prevent immune rejection of the implanted vascular stent, thereby addressing the problems of inflammation and intimal hyperplasia. The helical structure facilitates contraction and expansion, has good bending flexibility, and the added connecting ribs increase the radial support performance of the vascular stent, better achieving the effect of vascular remodeling. This invention has significant implications in terms of biodegradability, anti-immune rejection, and mechanical properties, and can be used for treatment in different locations such as peripheral and coronary vessels.